Magazine Article | June 1, 2018

Companies To Watch: Sensorion

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Addressing vertigo and hearing loss inside the inner ear.

SNAPSHOT
Sensorion is a public company in France developing new medicines for diseases of the inner ear, with two compounds in the pipeline: SENS- 111 for treating acute unilateral vestibulopathy (intense vertigo), and SENS-401 for treating hearing disorders such as sudden sensorineural hearing loss (SSNHL) and preventing others such as cisplatin-induced ototoxicity. Now in a Phase 2 trial, SENS-111 is a first-in-class, histamine H4 receptor antagonist. Entering Phase 2 development for SSNHL, SENS-401 is a 5-HT3 receptor antagonist with calcineurin inhibition mode of action.